Peer-influenced content. Sources you trust. No registration required. This is HCN.
Psych Congress Network
“Evenamide has the potential to treat the symptoms of schizophrenia more broadly, addressing also those poorly managed by the currently available antipsychotics.” — Ravi Anand, MD, Therapeutic Advances in Psychopharmacology
Psychiatry February 18th 2026
Renal + Urology News
“The WOLVERINE meta-analysis provides the strongest evidence to date that MDT improves progression-free survival, radiographic progression-free survival, and castration resistance-free survival.” — Tang et al., The Lancet Oncology
Oncology, Medical February 17th 2026
Cleveland Clinic Journal of Medicine (CCJM)
Studies have shown a mean effect size with CBTI of 0.96 compared with 0.87 for pharmacotherapy, suggesting similar efficacy in short term but CBTI seems to have longer-lasting effects.
Family Medicine/General Practice February 6th 2026
Psychiatrist.com
Treatment preferences shifted to include nonaugmentative antidepressants and electroconvulsive therapy based on changes in patient characteristics.
Psychiatry February 4th 2026
MDLinx
Silent inactivation (where neutralizing antibodies reduce enzymatic activity without clinical symptoms) can go undetected without therapeutic drug monitoring, leading to subtherapeutic asparagine depletion and increased relapse risk.
Hematology December 1st 2025
EP – Europace
In this 22-center study of repeat ablations following PFA, 45% of patients maintained complete pulmonary vein isolation from their initial procedure, with subsequent success rates varying significantly by arrhythmia type.
Cardiology February 10th 2025